within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AC06_Hexoprenaline;

model Hexoprenaline
  extends Pharmacolibrary.Drugs.ATC.R.R03AC06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03AC06</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hexoprenaline is a selective beta-2 adrenergic agonist previously used primarily as a bronchodilator for the management of asthma and chronic obstructive pulmonary disease (COPD), and also as a tocolytic agent to inhibit premature labor. Its medical use is limited or discontinued in many countries due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adult individuals, as published data specifically reporting model-based PK parameters are lacking.</p><h4>References</h4><ol><li><p>Brès, J, et al., &amp; Bressolle, F (1985). [Metabolism of beta-adrenergic substances. Therapeutic implications]. <i>Bulletin europeen de physiopathologie respiratoire</i> 21(5) 19s–34s. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2865990/\">https://pubmed.ncbi.nlm.nih.gov/2865990</a></p></li><li><p>Lipshitz, J, et al., &amp; Schneider, J (1981). Hexoprenaline pharmacokinetics in pregnant and nonpregnant sheep. <i>Research communications in chemical pathology and pharmacology</i> 34(1) 3–16. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7313303/\">https://pubmed.ncbi.nlm.nih.gov/7313303</a></p></li><li><p>Kamper, B, et al., &amp; Hertting, G (1973). [Pharmacokinetic studies on 3H-hexoprenaline in the rat]. <i>Arzneimittel-Forschung</i> 23(5) 721–729. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4740216/\">https://pubmed.ncbi.nlm.nih.gov/4740216</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Hexoprenaline;
